Form 4: LGND CFO Espinoza Sells Shares Under 10b5-1 Plan

Ligand Pharmaceuticals CFO Octavio Espinoza exercised stock options and subsequently sold a significant number of common shares under a pre-arranged 10b5-1 trading plan.

Summary

• Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc. (LGND), engaged in multiple transactions on March 4, 2026.
• Espinoza exercised employee stock options to acquire a total of 2,073 shares of common stock: 1,607 shares at an exercise price of $58.49 and 466 shares at an exercise price of $80.72.
• Concurrently, Espinoza sold a total of 13,023 shares of common stock in multiple transactions at weighted-average prices ranging from $198.7052 to $208.796.
• These transactions were conducted pursuant to a Rule 10b5-1 written trading plan adopted on November 19, 2025.
• Following these transactions, Espinoza's direct beneficial ownership of common stock decreased to 21,662 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the sales were pre-planned under a 10b5-1 plan, the significant reduction in the CFO's direct holdings could be interpreted by some investors as a lack of conviction in the company's near-term growth prospects.

Positives

• The exercise of stock options indicates that the options were in-the-money, suggesting the stock price was significantly above the exercise prices of $58.49 and $80.72.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were not based on immediate, non-public information.

Negatives

• A significant number of shares (13,023) were sold by a key executive, the Chief Financial Officer, which can be interpreted as a reduction in his direct stake in the company.
• The net effect of the transactions was a decrease in the CFO's beneficial ownership from an implied higher number (before sales) to 21,662 shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1.
• The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common occurrence in the biotechnology and pharmaceutical sectors, particularly when executives monetize vested equity compensation. While pre-planned sales mitigate concerns about opportunistic trading, a significant reduction in an executive's direct holdings can sometimes be viewed with caution by investors, especially if it's part of a broader trend among management.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Rule 10b5-1 plans for executive stock sales is a standard practice across industries, including biotech and pharma, to manage personal finances while adhering to insider trading regulations.
• While specific comparable companies or projects are not relevant for an individual's trading activity, the volume of sales by a CFO could be compared to similar executive sales at peer companies like Amgen, Gilead Sciences, or Biogen to gauge relative magnitude, though without context of total compensation or vesting schedules, direct comparisons are limited.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived negatively, potentially influencing investor sentiment and the stock price.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Key Dates

Recommendation

While the insider selling by the CFO is a negative signal, the transactions were pre-planned under a 10b5-1 plan, which mitigates the immediate concern of opportunistic trading. Without additional company-specific news or broader market context, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and executive sentiment.

Keywords

Ligand Pharmaceuticals, LGND, Octavio Espinoza, CFO, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation